Inflazome clinical trials to begin on Parkinson’s and Alzheimer’s
Roche, which bought Inflazome for €380 million last month is to begin six large clinical trials on drugs developed by Professor Luke O’Neill’s company
Roche, the Swiss pharmaceutical giant, is to begin six large clinical trials testing the efficacy of drugs developed by Professor Luke O’Neill’s Inflazome.
Inflazome, the biotech company founded by O’Neill and Professor Matt Cooper, was bought for €380 million last month.
The Swiss healthcare company has now decided to begin a series of large-scale trials which they hope could produce treatments for a wide range of ailments including Parkinson’s...
Subscribe from just €1 for the first month!
With any subscription you will have access to
Unlimited multi-device access to our iPad, iPhone and Android Apps
Unlimited access to our eReader library
Exclusive daily insight and opinion seven days a week
Create alerts to never miss a subject that matters to you
Get access to exclusive offers for subscribers on gifts and experiences
Get content from Business Post, Business Post Magazines, Connected, Tatler and Food & Wine
HSE chief: Ireland in ‘final countdown’ stage of vaccinations
The Health Service Executive is considering closing some mass vaccination centres in autumn as the uptake in jabs continues
Lucinda Creighton: We should harness Olympic glory to tackle our weight crisis
The incredible efforts of our Olympians in Tokyo are in sharp contrast to the fact that we are now the second most obese nation in the EU
Thérapie to offer egg freezing service to women in their 20s
The group best known for providing cosmetic Botox and laser hair removal has invested €10 million in three new fertility clinics